S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   378.88 (+1.28%)
AAPL   148.56 (-0.09%)
MSFT   309.15 (+0.00%)
FB   340.77 (+4.98%)
GOOGL   2,782.00 (+1.11%)
TSLA   1,029.11 (+13.13%)
AMZN   3,336.77 (+0.04%)
NVDA   232.50 (+2.31%)
BABA   176.42 (-0.72%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.30 (+1.20%)
AMD   122.50 (+2.24%)
MU   68.72 (+1.79%)
T   25.60 (+0.43%)
F   16.03 (-1.54%)
ACB   7.20 (+1.84%)
DIS   172.09 (+1.58%)
PFE   43.06 (-0.23%)
BA   212.95 (+-0.01%)
AMC   36.70 (+0.27%)
S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   378.88 (+1.28%)
AAPL   148.56 (-0.09%)
MSFT   309.15 (+0.00%)
FB   340.77 (+4.98%)
GOOGL   2,782.00 (+1.11%)
TSLA   1,029.11 (+13.13%)
AMZN   3,336.77 (+0.04%)
NVDA   232.50 (+2.31%)
BABA   176.42 (-0.72%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.30 (+1.20%)
AMD   122.50 (+2.24%)
MU   68.72 (+1.79%)
T   25.60 (+0.43%)
F   16.03 (-1.54%)
ACB   7.20 (+1.84%)
DIS   172.09 (+1.58%)
PFE   43.06 (-0.23%)
BA   212.95 (+-0.01%)
AMC   36.70 (+0.27%)
S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   378.88 (+1.28%)
AAPL   148.56 (-0.09%)
MSFT   309.15 (+0.00%)
FB   340.77 (+4.98%)
GOOGL   2,782.00 (+1.11%)
TSLA   1,029.11 (+13.13%)
AMZN   3,336.77 (+0.04%)
NVDA   232.50 (+2.31%)
BABA   176.42 (-0.72%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.30 (+1.20%)
AMD   122.50 (+2.24%)
MU   68.72 (+1.79%)
T   25.60 (+0.43%)
F   16.03 (-1.54%)
ACB   7.20 (+1.84%)
DIS   172.09 (+1.58%)
PFE   43.06 (-0.23%)
BA   212.95 (+-0.01%)
AMC   36.70 (+0.27%)
S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   378.88 (+1.28%)
AAPL   148.56 (-0.09%)
MSFT   309.15 (+0.00%)
FB   340.77 (+4.98%)
GOOGL   2,782.00 (+1.11%)
TSLA   1,029.11 (+13.13%)
AMZN   3,336.77 (+0.04%)
NVDA   232.50 (+2.31%)
BABA   176.42 (-0.72%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.30 (+1.20%)
AMD   122.50 (+2.24%)
MU   68.72 (+1.79%)
T   25.60 (+0.43%)
F   16.03 (-1.54%)
ACB   7.20 (+1.84%)
DIS   172.09 (+1.58%)
PFE   43.06 (-0.23%)
BA   212.95 (+-0.01%)
AMC   36.70 (+0.27%)
NASDAQ:OTIC

Otonomy Stock Forecast, Price & News

$2.00
+0.11 (+5.82 %)
(As of 10/25/2021 04:36 PM ET)
Add
Compare
Today's Range
$1.86
$2.00
50-Day Range
$1.22
$2.01
52-Week Range
$1.14
$6.98
Volume7,019 shs
Average Volume616,346 shs
Market Capitalization$113.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2
30 days | 90 days | 365 days | Advanced Chart
Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.


Otonomy logo

About Otonomy

Otonomy, Inc. operates as a biopharmaceutical company. It engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTIC
Employees
56
Year Founded
N/A

Sales & Book Value

Annual Sales
$270,000.00
Book Value
$1.37 per share

Profitability

Net Income
$-44.73 million
Net Margins
-20,278.95%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$113.36 million
Next Earnings Date
11/3/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.06 out of 5 stars

Medical Sector

505th out of 1,360 stocks

Pharmaceutical Preparations Industry

238th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Otonomy (NASDAQ:OTIC) Frequently Asked Questions

Is Otonomy a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Otonomy stock.
View analyst ratings for Otonomy
or view top-rated stocks.

What stocks does MarketBeat like better than Otonomy?

Wall Street analysts have given Otonomy a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Otonomy wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Otonomy's next earnings date?

Otonomy is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Otonomy
.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) announced its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. The biopharmaceutical company earned $0.04 million during the quarter, compared to analyst estimates of $0.07 million. Otonomy had a negative net margin of 20,278.95% and a negative trailing twelve-month return on equity of 67.24%.
View Otonomy's earnings history
.

How has Otonomy's stock price been impacted by Coronavirus (COVID-19)?

Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OTIC stock has decreased by 23.7% and is now trading at $2.00.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OTIC?

2 Wall Street analysts have issued 12 month price targets for Otonomy's stock. Their forecasts range from $5.50 to $11.00. On average, they anticipate Otonomy's share price to reach $7.50 in the next year. This suggests a possible upside of 275.0% from the stock's current price.
View analysts' price targets for Otonomy
or view top-rated stocks among Wall Street analysts.

Who are Otonomy's key executives?

Otonomy's management team includes the following people:
  • David A. Weber, President, Chief Executive Officer & Director
  • Paul E. Cayer, Chief Financial & Business Officer
  • Fabrice Piu, Vice President-Research & Preclinical Development
  • Robert Michael Savel, Chief Technical Officer
  • Alan C. Foster, Vice President-Research

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $2.00.

How much money does Otonomy make?

Otonomy has a market capitalization of $113.36 million and generates $270,000.00 in revenue each year. The biopharmaceutical company earns $-44.73 million in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Otonomy have?

Otonomy employs 56 workers across the globe.

What is Otonomy's official website?

The official website for Otonomy is www.otonomy.com.

Where are Otonomy's headquarters?

Otonomy is headquartered at 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (619) 323-2200 or via email at [email protected].


This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.